What's Hot

View all perspectives
      ➡️More DMARD-exposed pts w late-onset RA reduce long-term GC use than DMARD-unexposed
      ➡️Persistent GC use is com

      Mrinalini Dey DrMiniDey

      1 month ago
      ➡️More DMARD-exposed pts w late-onset RA reduce long-term GC use than DMARD-unexposed ➡️Persistent GC use is common ➡️In DMARD-exposed, GC use may be related to limited access to high-cost drugs ➡️In DMARD-unexposed, comorbidity burden may limit DMARD use Ab2606 #ACR24 @RheumNow
      How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)?

      ➡️75 pts with ARDs
      💉2-week #MTX di

      Mrinalini Dey DrMiniDey

      1 month ago
      How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)? ➡️75 pts with ARDs 💉2-week #MTX discontinuation after each dose of RZV ⏩Significant boost in immune response without difference in flare rates Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be
      A#2649
      Relapsing Polychondritis
      Latent Class Analysis to define clinical phenotypes of heterogeneous dx
      Type 1- ear, nos

      Eric Dein ericdeinmd

      1 month ago
      A#2649 Relapsing Polychondritis Latent Class Analysis to define clinical phenotypes of heterogeneous dx Type 1- ear, nose, subglottic stenosis 2- tracheo/bronchomalacia 3- absence tracheomalacia Decision tree to classify pts in subgroups #ACR24 @RheumNow https://t.co/xpZedPVl7f
      Loiseau et al. 4700 pSS, 47000 comparators. pSS associated with increased risk of every CV/VTE outcome. Did not have tha

      Richard Conway RichardPAConway

      1 month ago
      Loiseau et al. 4700 pSS, 47000 comparators. pSS associated with increased risk of every CV/VTE outcome. Did not have that in my priors! @RheumNow #ACR24 Abstr#2631 https://t.co/QKemUhbcG8 https://t.co/twpjdS2L63
      A#2650
      MRI can show extent of vessel wall inflamm to guide severity of GCA

      Brain & orbital MRI performed
      Assessed 7

      Eric Dein ericdeinmd

      1 month ago
      A#2650 MRI can show extent of vessel wall inflamm to guide severity of GCA Brain & orbital MRI performed Assessed 7 arteries bilaterally -> CAMRIS-GCA MRI score (0-10) 33 GCA (17 ocular), 41 not GCA CAMRIS-GCA ass w/ ocular GCA, higher severity. Improved w Rx @RheumNow #ACR24 https://t.co/19XCuZJXqF
      Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier

      sheila RHEUMarampa

      1 month ago
      Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4
      A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis

      Antoni Chan MD (Prof) synovialjoints

      1 month ago
      A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/JEqVPLGNfu
      Did you know?
      #Lupus arthritis have clinical and US classifications.
      On MRI, findings will show:
      - periarticular hyperp

      sheila RHEUMarampa

      1 month ago
      Did you know? #Lupus arthritis have clinical and US classifications. On MRI, findings will show: - periarticular hyperplastic tissue - capsular swelling - edematous tenosynovitis @RheumNow #ACR24 @rheumarhyme @theactiverheum https://t.co/EoKh2Q3V9Z
      McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses

      Richard Conway RichardPAConway

      1 month ago
      McInnes et al. 24 week phase 2 ARGO trial. Sonelokimab, IL-17A- and IL-17F-inhibiting nanobody, in PsA. ACR50 responses shown in picture. Good efficacy across domains, but this is phase 2, will await the phase 3. @RheumNow #ACR24 Abstr#2582 https://t.co/FQflZMPes0 https://t.co/DATqo37yib
      A#2582 McInnes
      Sonelokimab - IL17A,F nanobody
      Prior P2 in PsO, HS
      ARGO: P2 W24 RCT
      Significant improv in ACR response
      Hi

      Eric Dein ericdeinmd

      1 month ago
      A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK
      SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study.

      Reasons for

      sheila RHEUMarampa

      1 month ago
      SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi
      Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104

      Richard Conway RichardPAConway

      1 month ago
      Merrill et al. SLEek LTE. ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib monotherapy in SLE. 104 week data. SRI-4 85.4%, 82.1%, and 61.3% in the ABBV-599 HD, UPA 30 mg, and PBO to ABBV-599 HD group @RheumNow #ACR24 Abstr#2577 https://t.co/wc6Mb13U4O https://t.co/Xu1pMhAUrG
      Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutan

      TheDaoIndex KDAO2011

      1 month ago
      Disseminated acanthamoeba : pt with modular painful skin lesions on his palms and scalp— initially dx’d with a cutaneous vasculitis- he got worse with immunosuppression. Imaging and histology shown #ThievesMarket #ACR24 @RheumNow https://t.co/FjJ0Sk0Kxt
      A#2583
      Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring
      MOSAIC P4 open label trial
      Reduction in inflamm

      Eric Dein ericdeinmd

      1 month ago
      A#2583 Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring MOSAIC P4 open label trial Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation @RheumNow #ACR24 https://t.co/3GKEGJbtdc
      A#2584 Mease
      Zasocitinib TAK-279 - potent, selective TYK2i
      P2b, 12w PsA RCT
      15/30 mg - similar response, better than PBO

      Eric Dein ericdeinmd

      1 month ago
      A#2584 Mease Zasocitinib TAK-279 - potent, selective TYK2i P2b, 12w PsA RCT 15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS 29% MDA v 13% PBO Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted @RheumNow #ACR24 https://t.co/1eqD9R5fLe

      Podcasts

      • Bah Humbug Vitamin D (12.20.2024)
      • 54K Peptic Ulcers Annually (12.13.2024)
      • Don’t Buy Guitars (12.6.2024)

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright 2024 All Rights Reserved.

      ×